Inflammatory bowel disease (IBD) is a major global health concern, with an estimated 1.6 million cases in the US alone. While there are many treatments available, they are often ineffective and can cause harmful side effects. A major reason clinically successful IBD therapies remain elusive is because current model systems cannot replicate key mechanistic aspects of the epithelial inflammatory response in humans.
In this webinar brought to you by Altis Biosystems, Bryan McQueen will describe the development of a new stem-cell derived intestinal epithelium model system for testing IBD therapeutic efficacy. Using this model system, researchers developed a suite of assays to probe epithelial barrier disruption, cytotoxicity, and pro-inflammatory cytokine release in response to the activation of prototypical IBD-associated cellular pathways.
Comments are closed.